Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Congenital Hypothalamic Obesity
NCT06760546Phase 3Recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of setmelanotide in hypothalamic obesity (HO), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Mean percent change in Body Mass Index at 26 weeks. Started Sep 2025; status: recruiting.
02
Drugs
setmelanotide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT06760546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760546.